Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 Å resolution crystal structures of HIV-1 protease mutants with substrate analogs

FEBS Journal

Volumn 272, Issue 20, 2005, Pages 5265-5277

  Tie, Yunfeng ^a   Boross, Peter I ^a,b   Wang, Yuan Fang ^a   Gaddis, Laquasha ^a   Liu, Fengling ^a   Chen, Xianfeng ^a   Tozser, Jozsef ^b   Harrison, Robert W ^a   Weber, Irene T ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Catalysis; Crystal structure; Drug resistance; HIV 1 protease; Substrate analog

Indexed keywords

HYDROGEN; MUTANT PROTEIN; PEPTIDE DERIVATIVE; PROTEIN P6; PROTEINASE; UNCLASSIFIED DRUG; VIRUS ENZYME; VIRUS PROTEASE; WATER;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; GENE MUTATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; KINETICS; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SUBSTITUTION; BINDING SITES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, VIRAL; ELECTRONS; ELECTROSTATICS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; HYDROGEN BONDING; INDINAVIR; KINETICS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTATION; PROTEIN STRUCTURE, TERTIARY; SUBSTRATE SPECIFICITY; SULFONAMIDES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 27144554995     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2005.04923.x     Document Type: Article

References (43)

1. Darke PL, Nutt RF, Brady SF, Garsky VM, Ciccarone TM, Leu CT et al. (1988) HIV-1 protease specificity of peptide cleavage is sufficient for processing of Gag and Pol polyproteins. Biochem Biophys Res Commun 156, 297-303.
2. Oroszlan S & Luftig RB (1990) Retroviral proteases. Curr Top Microbiol Immunol 157, 153-185.
3. Wlodawer A & Erickson JW (1993) Structure-based inhibitors of HIV-1 protease. Annu Rev Biochem 62, 543-585.
4. Erickson JW, Gulnik SV & Markowitz M (1999) Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS Res Hum Retroviruses 13, S189-S204.
5. Shafer RW, Winters MA, Palmer S & Merigan TC (1998) Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann Intern Med 128, 906-911.
6. Shafer RW (2002) Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 15, 247-277.
7. Wu TD, Schiffer CA, Gonzales MJ, Taylor J, Kantor R, Chou S et al. (2003) Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol 77, 4836-4847.
8. Prabu-Jeyabalan M, Nalivaika E & Schiffer CA (2002) Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 10, 369-381.
9. Prabu-Jeyabalan M, Nalivaika EA, King NM & Schiffer CA (2003) Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy. J Virol 77, 1306-1315.
10. Prabu-Jeyabalan M, Nalivaika EA, King NM & Schiffer CA (2004) Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J Virol 78, 12446-12454.
11. Weber IT, Wu J, Adomat J, Harrison RW, Kimmel AR, Wondrak EM & Louis JM (1997) Crystallographic analysis of HIV-1 protease with an analog of the conserved CA-p2 substrate: Interactions with frequently occurring Glu at P2′ position of substrate. Eur J Biochem 249, 523-530.
12. Mahalingam B, Louis JM, Hung J, Harrison RW & Weber IT (2001) Structural implications of drug resistant mutants of HIV-1 protease: High resolution crystal structures of the mutant protease/substrate analogue complexes. Proteins Struct Funct Genet 43, 455-464.
13. Mahalingam B, Boross P, Wang YF, Louis JM, Fischer CC, Tozser J, Harrison RW & Weber IT (2002) Combining mutations in HIV-1 protease to understand mechanisms of resistance. Proteins Struct Funct Genet 48, 107-116.
14. Pettit SC, Moody MD, Wehbie RS, Kaplan AH, Nantermet PV, Klein CA & Swanstrom R (1994) The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol 68, 8017-8027.
15. Louis JM, Nashed NT, Parris KD, Kimmel AR & Jerina DM (1994) Kinetics and mechanism of autoprocessing of human immunodeficiency virus type 1 protease from an analog of the Gag-Pol polyprotein. Proc Natl Acad Sci USA 91, 7970-7974.
16. Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L & Lamarre D (1997) Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 71, 1089-1096.
17. Robinson LH, Myers RE, Snowden BW, Tisdale M & Blair ED (2000) HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays. AIDS Res Hum Retroviruses 16, 1149-1156.
18. Zhang YM, Imamichi H, Imamichi T, Lane HC, Falloon J, Vasudevachari MB & Salzman NP (1997) Drug resistance during indinavir therapy is caused by mutations in the protease gene and its Gag substrate cleavage sites. J Virol 71, 6662-6670.
19. Barrie KA, Perez EE, Lamers SL, Farmerie WG, Dunn BM, Sleasman JW & Goodenow MM (1996) Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within Gag/Pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. Virology 219, 407-416.
20. Bally F, Martinez R, Peters S, Sudre P & Telenti A (2000) Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res Hum Retroviruses 16, 1209-1213.
21. Feher A, Weber IT, Bagossi P, Boross P, Mahalingam B, Louis JM, Copeland TD, Torshin IY, Harrison RW & Tozser J (2002) Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. Eur J Biochem 269, 4114-4120.
22. Tozser J, Blaha I, Copeland TD, Wondrak EM & Oroszlan S (1991) Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins. FEBS Lett 281, 77-80.
23. Tomasselli AG, Olsen MK, Hui JO, Staples DJ, Sawyer TK, Heinrikson RL & Tomich CS (1990) Substrate analogue inhibition and active site titration of purified recombinant HIV-1 protease. Biochemistry 29, 264-269.
24. Klabe RM, Bacheler LT, Ala PJ, Erickson-Viitanen S & Meek JL (1998) Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency. Biochemistry 37, 8735-8742.
25. Tie Y, Boross PI, Wang YF, Gaddis L, Hussain AK, Leshchenko S et al. (2004) High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains. J Mol Biol 338, 341-352.
26. Rose RB, Craik CS & Stroud RM (1998) Domain flexibility in retroviral proteases: structural implications for drug resistant mutations. Biochemistry 37, 2607-2621.
27. Ishima R, Freedberg DI, Wang YX, Louis JM & Torchia DA (1999) Flap opening and dimer interface flexibility in the free and inhibitor-bound HIV protease, and their implications for function. Struct Fold Des 7, 1047-1055.
28. Piana S, Carloni P & Rothlisberger U (2002) Drug resistance in HIV-1 protease: Flexibility-assisted mechanism of compensatory mutations. Protein Sci 11, 2393-2402.
29. Perryman AL, Lin JH & McCammon JA (2004) HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs. Protein Sci 13, 1108-1123.
30. Grzesiek S, Bax A, Nicholson LK, Yamazaki T, Wingfield PT, Stahl SJ et al. (1994) NMR evidence for the displacement of a conserved interior water molecule by a non-peptide cyclic urea based HIV protease inhibitor. J Am Chem Soc 116, 1581-1582.
31. Wang YX, Freedberg DI, Yamazaki T, Wingfield PT, Stahl SJ, Kaufman JD et al. (1996) Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272. Biochemistry 35, 9945-9950.
32. Baldwin ET, Bhat TN, Liu B, Pattabiraman N & Erickson JW (1995) Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase. Nat Struct Biol 2, 244-249.
33. Piana S, Carloni P & Parrinello M (2002) Role of conformational fluctuations in the enzymatic reaction of HIV-1 protease. J Mol Biol 319, 567-583.
34. Mahalingam B, Wang YF, Boross PI, Tozser J, Louis JM, Harrison RW & Weber IT (2004) Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site. Eur J Biochem 271, 1516-1524.
35. Slee DH, Laslo KL, Elder JH, Ollmann IR, Gustchina A, Kervinen J, Zdanov A, Wlodawer A & Wong CH (1995) Selectivity in the inhibition of HIV and FIV protease: inhibitory and mechanistic studies of pyrrolidine-containing alpha-keto amide and hydroxyethylamine core structures. J Am Chem Soc 117, 11867-11878.
36. Silva AM, Cachau RE, Sham HL & Erickson JW (1996) Inhibition and catalytic mechanism of HIV-1 aspartic protease. J Mol Biol 255, 321-346.
37. Wondrak EM & Louis JM (1996) Influence of flanking sequences on the dimer stability of human immunodeficiency virus type 1 protease. Biochemistry 35, 12957-12962.
38. Louis JM, Wondrak EM, Copeland TD, Smith CA, Mora PT & Oroszlan S (1989) Chemical synthesis and expression of the HIV-1 protease gene in E. coli. Biochem Biophys Res Commun 159, 87-94.
39. Otwinowski Z & Minor W (1997) Processing of X-ray diffraction data in oscillation mode. Methods Enzymol 276, 307-326.
40. Navaza J (1994) AMoRe: An automated package for molecular replacement. Acta Crystallogr A 50, 157-163.
41. Sheldrick GM & Schneider TR (1997) SHELXL: High resolution refinement. Methods Enzymol 277, 319-343.
42. Jones TA, Zou JY, Cowan SW & Kjeldgaard M (1991) Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 47, 110-119.
43. Kraulis PJ (1991) MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 24, 946-950.